TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15361773

Group type: EXPERIMENTAL
Intervention: Isoproterenol bolus (0.1, 0.25, 0.5, 1.0 and 2.0 microg/m)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Isoproterenol infusion (10, 20 and 40 ng/kg per min for 30 min)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Baseline heart rate
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Urinary noradrenaline
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Plasma noradrenaline
Number of subjects: 38
Study: 11220439

Group type: EXPERIMENTAL
Intervention: Power primed communals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Power primed exchangers
Number of subjects: 0
Study: 9863121

Group type: EXPERIMENTAL
Intervention: Chinese herbs combined with chemotherapy
Number of subjects: 167

Group type: COMPARATOR
Intervention: Chemotherapy only (Control)
Number of subjects: 167
Study: 8296357

Group type: EXPERIMENTAL
Intervention: Permethrin-impregnated bed net (PIB)
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Family size non-impregnated bed net (FNIB)
Number of subjects: 341

Group type: COMPARATOR
Intervention: Non-impregnated bed net (NIB)
Number of subjects: 341

Group type: COMPARATOR
Intervention: No net
Number of subjects: 341
Study: 3528087

Group type: EXPERIMENTAL
Intervention: RT + MISO (400 mg/M2 2‐4 hours prior to RT daily, maximum 12 gm/M2)
Number of subjects: 120

Group type: COMPARATOR
Intervention: RT alone
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: RT + MISO
Number of subjects: 120
Study: 28404217

Group type: EXPERIMENTAL
Intervention: Ingroup members
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Outgroup members
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Social group membership
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Younger children (3-6 years)
Number of subjects: 0
Study: 27531289

Group type: EXPERIMENTAL
Intervention: Modified phaco capsulotomy technique
Number of subjects: 80

Group type: COMPARATOR
Intervention: High-viscosity OVD–assisted capsulorhexis (sodium hyaluronate 2.0%)
Number of subjects: 80
Study: 24045440

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy followed by local therapy (radiation and/or surgery) and adjuvant chemotherapy
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Chemotherapy/surgery alone
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Radiochemotherapy only
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Combined radiochemotherapy/surgery
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Embryonal histology
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Alveolar histology
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Fecal incontinence
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Quality of life (QOL)
Number of subjects: 32
Study: 22562409

Group type: EXPERIMENTAL
Intervention: Romiplostim
Number of subjects: 234

Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 234
Study: 20949292

Group type: EXPERIMENTAL
Intervention: Intraoperative microelectrode recording (MER) during STN-DBS
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Intraoperative microelectrode recording (MER) during GPi-DBS
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Intraoperative test stimulation
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Final electrode location selection based on MER activity
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: MER activity intensity
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Macro-test stimulation
Number of subjects: 85
Study: 18564626

Group type: EXPERIMENTAL
Intervention: Etoricoxib (45 mg on day 2, 90 mg on day 3)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo (day 1)
Number of subjects: 65
Study: 16033730

Group type: EXPERIMENTAL
Intervention: Insulin glulisine (premeal)
Number of subjects: 860

Group type: EXPERIMENTAL
Intervention: Insulin glulisine (postmeal)
Number of subjects: 860

Group type: COMPARATOR
Intervention: Regular human insulin (premeal)
Number of subjects: 860
Study: 12472702

Group type: EXPERIMENTAL
Intervention: Methohexital (10 mg.ml‐1) combined with remifentanil (6.67 micro g.ml‐1)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Propofol and fentanyl
Number of subjects: 162
Study: 10051728

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate aqueous nasal spray (FP) 200 microg once daily for 4 weeks
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate aqueous nasal spray (FP)
Number of subjects: 16
Study: 7572828

Group type: EXPERIMENTAL
Intervention: Well-designed jobs and supportive workplace relationships and policies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Informal sources of support
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Formal sources of support
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: African American workers, especially women
Number of subjects: 0
Study: 2140546

Group type: EXPERIMENTAL
Intervention: Clarithromycin (two 250 mg tablets twice daily)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Amoxycillin (two 500 mg capsules twice daily)
Number of subjects: 120
Study: 498423

Group type: EXPERIMENTAL
Intervention: Daunorubicin on day 1 + ARA‐C on days 1‐5
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Daunorubicin on days 1 and 2 + ARA‐C on days 4‐8
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Daunorubicin-DNA complex on days 1‐2 + ARA‐C on days 4‐8
Number of subjects: 44
Study: 31136470

Group type: EXPERIMENTAL
Intervention: Projection method
Number of subjects: 60

Group type: COMPARATOR
Intervention: Doppler method
Number of subjects: 60
Study: 28892233

Group type: EXPERIMENTAL
Intervention: HA microneedle patch
Number of subjects: 34

Group type: COMPARATOR
Intervention: HA essence application
Number of subjects: 34
Study: 26202042

Group type: EXPERIMENTAL
Intervention: Cooling intervention to maintain normothermia (36.5‐37 °C) during 48 hours.
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Time spent with a temperature below 38.4 °C during the cooling intervention.
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Time spent with a heart rate below 95 b/min during the cooling intervention.
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Time spent with a temperature below 38.4 °C as a mediator of mortality.
Number of subjects: 197
Study: 23689006

Group type: EXPERIMENTAL
Intervention: Revascularization treatment with calcium hydroxide
Number of subjects: 34

Group type: COMPARATOR
Intervention: Conventional apexification procedures (Control)
Number of subjects: 34
Study: 21747052

Group type: EXPERIMENTAL
Intervention: Highest-carbohydrate diet
Number of subjects: 738

Group type: EXPERIMENTAL
Intervention: Lowest-carbohydrate diet
Number of subjects: 738
Study: 19269895

Group type: EXPERIMENTAL
Intervention: Concomitant and adjuvant temozolomide with radiotherapy
Number of subjects: 573

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 573
Study: 17110006

Group type: EXPERIMENTAL
Intervention: One miniplate
Number of subjects: 62

Group type: COMPARATOR
Intervention: Two miniplates
Number of subjects: 62
Study: 14742382

Group type: EXPERIMENTAL
Intervention: Fentanyl HCl PCTS 40 microg
Number of subjects: 205

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 205
Study: 11367972

Group type: COMPARATOR
Intervention: Listerine Antiseptic (L)
Number of subjects: 316

Group type: COMPARATOR
Intervention: Colgate Total toothpaste (T)
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Control toothpaste/control rinse (P)
Number of subjects: 316
Study: 9406261

Group type: EXPERIMENTAL
Intervention: System of care services
Number of subjects: 350

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 350
Study: 8428561

Group type: EXPERIMENTAL
Intervention: Complete alcohol abstinence for one year
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Resuming alcohol abuse
Number of subjects: 30
Study: 3595068

Group type: EXPERIMENTAL
Intervention: Fasting (10 mg nifedipine)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Low-fat meal (10 mg nifedipine)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: High-fat meal (10 mg nifedipine)
Number of subjects: 15
Study: 31886707

Group type: EXPERIMENTAL
Intervention: Intravitreal dexamethasone implant
Number of subjects: 60

Group type: COMPARATOR
Intervention: Oral acetazolamide (500 mg/day)
Number of subjects: 60
Study: 30176845

Group type: EXPERIMENTAL
Intervention: Systematic self-monitoring (5 times per day) and weekly personalized feedback on positive affect and activities ("Do"-module)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Systematic self-monitoring (5 times per day) and weekly personalized feedback on negative affect and thinking patterns ("Think"-module)
Number of subjects: 150

Group type: COMPARATOR
Intervention: No additional intervention (control group)
Number of subjects: 150
Study: 27229682

Group type: EXPERIMENTAL
Intervention: Let's Move It intervention (group sessions, poster campaign, sitting reduction, enhancement of PA opportunities)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control group (standard curriculum)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Let's Move It intervention
Number of subjects: 57
Study: 25239716

Group type: EXPERIMENTAL
Intervention: Catheter use noted in postadmission records
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: NHSN symptoms noted
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Potential NHSN CAUTI
Number of subjects: 294
Study: 24407896

Group type: EXPERIMENTAL
Intervention: Total intravenous anaesthesia with TCI (Group A)
Number of subjects: 337

Group type: EXPERIMENTAL
Intervention: Balanced anaesthesia (Group B)
Number of subjects: 337

Group type: EXPERIMENTAL
Intervention: Balanced anaesthesia (Group C)
Number of subjects: 337

Group type: EXPERIMENTAL
Intervention: Balanced anaesthesia (Group D)
Number of subjects: 337
Study: 21312290

Group type: EXPERIMENTAL
Intervention: Amantadine (100-150 mg/day depending on weight)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Methylphenidate (20-30 mg/day)
Number of subjects: 40
Study: 18186057

Group type: EXPERIMENTAL
Intervention: Biological/genetic explanation of anorexia nervosa
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sociocultural explanation of anorexia nervosa
Number of subjects: 0
Study: 16817177

Group type: EXPERIMENTAL
Intervention: 0.25 mg/kg abciximab bolus administered early in the emergency department
Number of subjects: 80

Group type: COMPARATOR
Intervention: 0.25 mg/kg abciximab bolus administered late in the catheterization laboratory
Number of subjects: 80
Study: 12538427

Group type: EXPERIMENTAL
Intervention: Acetylcholine infusion
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: L‐NMMA (NO synthase inhibitor)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Nitroprusside infusion
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: L‐NMMA
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Vascular cell adhesion molecule-1
Number of subjects: 39
Study: 10887714

Group type: EXPERIMENTAL
Intervention: Chronic Pain Self‐Management Program (CPSMP)
Number of subjects: 110
Study: 8882255

Group type: EXPERIMENTAL
Intervention: 0.1 mg intrathecal morphine
Number of subjects: 50

Group type: COMPARATOR
Intervention: 0.2 mg intrathecal morphine
Number of subjects: 50
Study: 1658648

Group type: EXPERIMENTAL
Intervention: Plasma exchange twice weekly for three weeks
Number of subjects: 39

Group type: COMPARATOR
Intervention: Sham plasma exchange
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Plasma exchange in open trial after sham exchange
Number of subjects: 39
Study: 6395905

Group type: EXPERIMENTAL
Intervention: Group progressive relaxation training
Number of subjects: 45

Group type: COMPARATOR
Intervention: Individual EMG biofeedback training
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo group listening to taped children's stories
Number of subjects: 45
Study: 31758382

Group type: EXPERIMENTAL
Intervention: Interferential currents (IFC)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 52
Study: 30779333

Group type: EXPERIMENTAL
Intervention: SMART-based treatment (online lessons, self-monitoring, feedback, monthly weigh-ins)
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: GROUP-based treatment (weekly meetings for 6 months, biweekly for 6 months, monthly for 6 months, self-monitoring via paper diaries with written feedback)
Number of subjects: 276

Group type: COMPARATOR
Intervention: CONTROL (self-monitoring via paper diaries with written feedback and monthly weigh-ins)
Number of subjects: 276
Study: 28134840

Group type: EXPERIMENTAL
Intervention: A2 milk (500 mL)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Regular milk (500 mL)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo (PLA) (500 mL)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: A2 milk
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Regular milk
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Milk treatments (A2 and regular)
Number of subjects: 21
Study: 25856225

Group type: EXPERIMENTAL
Intervention: Ibandronate 150 mg monthly
Number of subjects: 69

Group type: COMPARATOR
Intervention: Risedronate 35 mg weekly
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 69
Study: 23283923

Group type: EXPERIMENTAL
Intervention: Xylitol lozenges (5 lozenges of 1.0 gram daily for 33 months)
Number of subjects: 691

Group type: COMPARATOR
Intervention: Placebo lozenges (5 lozenges daily for 33 months)
Number of subjects: 691
Study: 20868639

Group type: EXPERIMENTAL
Intervention: Extended dosing (every second day)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Daily dosing (usual medication)
Number of subjects: 35
Study: 19833743

Group type: COMPARATOR
Intervention: Duloxetine
Number of subjects: 0
Study: 16754827

Group type: EXPERIMENTAL
Intervention: Antibullying school program
Number of subjects: 3816

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 3816
Study: 15796091

Group type: EXPERIMENTAL
Intervention: PMBL treatment (sublingual tablet taken for ten consecutive days over three consecutive months)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: PMBL treatment
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control group (untreated children)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Device for PMBL treatment
Number of subjects: 89
Study: 11405516

Group type: EXPERIMENTAL
Intervention: Self-treatment guidelines (group S)
Number of subjects: 245

Group type: COMPARATOR
Intervention: Control group (group C)
Number of subjects: 245
Study: 9010904

Group type: EXPERIMENTAL
Intervention: Community education programs combined with low-cost mobile mammography van services for 2 years
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-cost mobile mammography van services only
Number of subjects: 0
Study: 7635647

Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal angioplasty (PTA)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Arteriography alone (Control)
Number of subjects: 21
Study: 3582484

Group type: EXPERIMENTAL
Intervention: Subcutaneous terbutaline (0.25 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 30785636

Group type: EXPERIMENTAL
Intervention: Ego depletion
Number of subjects: 0
Study: 29023624

Group type: EXPERIMENTAL
Intervention: Pedicled buccal fat pad with Emdogain (group I; n = 5)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Pedicled buccal fat pad alone (group II; n = 5)
Number of subjects: 10
Study: 26141306

Group type: EXPERIMENTAL
Intervention: Cathasept 4% locks
Number of subjects: 117

Group type: COMPARATOR
Intervention: Heparin 5,000 U/mL locks
Number of subjects: 117
Study: 22776860

Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 262

Group type: COMPARATOR
Intervention: Denosumab (after 4 years of placebo)
Number of subjects: 262

Group type: COMPARATOR
Intervention: Placebo transitioning to Denosumab
Number of subjects: 262
Study: 21610564

Group type: EXPERIMENTAL
Intervention: Preferential hyperacuity perimetry (PHP)
Number of subjects: 200

Group type: COMPARATOR
Intervention: No intervention (before use of PHP)
Number of subjects: 200
Study: 19610504

Group type: EXPERIMENTAL
Intervention: Single layer continuous technique (group A, n=24)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Double layer continuous technique (group B, n=26)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Overall hospital mortality
Number of subjects: 50
Study: 16273330

Group type: EXPERIMENTAL
Intervention: Mechanical bowel preparation (polyethylene glycol; Group 1)
Number of subjects: 50

Group type: COMPARATOR
Intervention: No preparation (Group 2)
Number of subjects: 50
Study: 12684804

Group type: EXPERIMENTAL
Intervention: Subdiaphragmatic drain
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (no drain)
Number of subjects: 70
Study: 10632003

Group type: EXPERIMENTAL
Intervention: Air (group I)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 2% hydroxypropyl methylcellulose (HPMC) (group II)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Balanced saline solution (BSS) (group III)
Number of subjects: 40

Group type: COMPARATOR
Intervention: No adjunct (group IV)
Number of subjects: 40
Study: 9110100

Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg/day for six weeks
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 8237626

Group type: EXPERIMENTAL
Intervention: 10 mg metoclopramide by intravenous bolus
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 10 mg metoclopramide orally
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 10 mg metoclopramide (both intravenous and oral)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Liver volume measurement
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Bio-availability measurement
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Pharmacokinetic parameters measurement
Number of subjects: 18
Study: 4036848

Group type: EXPERIMENTAL
Intervention: 150 micrograms Se/day as selenomethionine with methionine
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 150 micrograms Se/day as sodium selenite with methionine
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 150 micrograms Se/day as sodium selenite without methionine
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 150 micrograms Se/day as selenomethionine without methionine
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Selenium supplementation (general)
Number of subjects: 50
Study: 31919319

Group type: EXPERIMENTAL
Intervention: hCG intrauterine perfusion group
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control group (G2 fluid)
Number of subjects: 140
Study: 29614960

Group type: EXPERIMENTAL
Intervention: Chair based exercise (CCBE) delivered once a week in day centres and community groups, and twice a week in care homes.
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Chair based exercise (CCBE)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Group reminiscence
Number of subjects: 128

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 128
Study: 27622997

Group type: EXPERIMENTAL
Intervention: Nivolumab 1 mg/kg plus ipilimumab 3 mg/kg
Number of subjects: 142

Group type: COMPARATOR
Intervention: Ipilimumab 3 mg/kg plus placebo
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab
Number of subjects: 142

Group type: COMPARATOR
Intervention: Ipilimumab alone
Number of subjects: 142
Study: 25009957

Group type: EXPERIMENTAL
Intervention: Contingency between high-amplitude sucking and presentation of maternal voice
Number of subjects: 24

Group type: COMPARATOR
Intervention: Yoked control group
Number of subjects: 24
Study: 22483371

Group type: EXPERIMENTAL
Intervention: Ballroom dance program (EG)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 75
Study: 20682687

Group type: EXPERIMENTAL
Intervention: Metformin intervention
Number of subjects: 2994

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 2994
Study: 17335299

Group type: EXPERIMENTAL
Intervention: Agalsidase beta (Fabrazyme)
Number of subjects: 0
Study: 16034448

Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg QD (Treatment phase-1)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Placebo (Placebo phase)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg QD (Treatment phase-2)
Number of subjects: 21
Study: 12047009

Group type: EXPERIMENTAL
Intervention: Combination antipsychotics (specifically augmentation of clozapine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clozapine (as a monotherapy)
Number of subjects: 0
Study: 10413398

Group type: EXPERIMENTAL
Intervention: Technologically advanced assessment methods (audio, computer, video)
Number of subjects: 1952

Group type: COMPARATOR
Intervention: Traditional assessment methods (written, face-to-face)
Number of subjects: 1952
Study: 8680294

Group type: EXPERIMENTAL
Intervention: Computerized tracking program for resident-patient encounters
Number of subjects: 0
Study: 2193265

Group type: EXPERIMENTAL
Intervention: Oral antibiotic therapy (cephalexin 500 mg every 6 hours)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Intravenous antibiotic therapy (cephalothin 1 g every 6 hours)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Both groups (oral and IV)
Number of subjects: 90
Study: 361000

Group type: EXPERIMENTAL
Intervention: Diazepam (5 mg every 8 hours when rectal temperature >= 38.5°C)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Phenobarbitone (3.5 +/- 1 mg/kg per day)
Number of subjects: 195
Study: 31502032

Group type: EXPERIMENTAL
Intervention: HoLEP
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: ThuLEP
Number of subjects: 116
Study: 31551378

Group type: EXPERIMENTAL
Intervention: Health and PA counselling group
Number of subjects: 450

Group type: COMPARATOR
Intervention: Relaxation group (control)
Number of subjects: 450
Study: 27327566

Group type: EXPERIMENTAL
Intervention: 400 IU of supplementary vitamin E
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Supplemented group
Number of subjects: 99
Study: 26330594

Group type: EXPERIMENTAL
Intervention: Early mobilisation (n = 97)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Standard rehabilitation (n = 92)
Number of subjects: 189